Arbutus Biopharma (ABUS) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arbutus Biopharma has reported promising results from their Phase 2a trials of imdusiran, showing potential as a key treatment for chronic hepatitis B. The company is reshaping its strategy by focusing on the development of imdusiran and cutting down its workforce by 40% to extend its cash runway until late 2026.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.